{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:02:53Z","timestamp":1773316973264,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T00:00:00Z","timestamp":1748131200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007761","name":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007761","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ad.2025.05.012","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T11:05:24Z","timestamp":1748430324000},"page":"T764-T768","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["[Translated article] AEDV BIOBADADERM Registry: 15 Year-Contribution to Psoriasis Therapy Safety"],"prefix":"10.1016","volume":"116","author":[{"given":"D.P.","family":"Ruiz-Genao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gonz\u00e1lez-Quesada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Sahuquillo-Torralba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Rivera-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Descalzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Garc\u00eda-Doval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2025.05.012_bib0205","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ad.2010.10.016","article-title":"BIOBADADERM: registro espa\u00f1ol de acontecimientos adversos de terapias biol\u00f3gicas en dermatolog\u00eda. Primer informe","volume":"102","author":"Rivera","year":"2011","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2025.05.012_bib0210","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1001\/archdermatol.2011.2768","article-title":"Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs. eligible for randomized controlled trials","volume":"148","author":"Garcia-Doval","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ad.2025.05.012_bib0215","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/bjd.14776","article-title":"Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts","volume":"176","author":"Garcia-Doval","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.012_bib0220","doi-asserted-by":"crossref","first-page":"502","DOI":"10.3109\/09546634.2015.1034070","article-title":"Use of off-label doses is frequent in biologic therapy for moderate to severe psoriasis: a cross-sectional study in clinical practice","volume":"26","author":"Carrascosa","year":"2015","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.ad.2025.05.012_bib0225","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/jdv.12492","article-title":"Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008\u20132013 results of the Biobadaderm registry","volume":"29","author":"Carretero","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.05.012_bib0230","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1111\/jdv.14314","article-title":"Adverse events associated with discontinuation of the biologics\/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registr Biobadaderm","volume":"31","author":"Belinchon","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.05.012_bib0235","first-page":"ljad382","article-title":"Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry","author":"Lluch-Galcera","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.012_bib0240","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jid.2016.08.034","article-title":"Infections in moderate to severe psoriasis patients treated with biological drugs compared to classic systemic drugs: Findings from the BIOBADADERM Registry","volume":"137","author":"Davila-Seijo","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ad.2025.05.012_bib0245","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","article-title":"Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report","volume":"48","author":"G\u00f3mez-Reino","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ad.2025.05.012_bib0250","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1111\/jdv.12011","article-title":"Latent tuberculosis infection and active tuberculosis in patients with psoriasis: a study on the incidence of tuberculosis and the prevalence of latent tuberculosis disease in patients with moderate-severe psoriasis in Spain","volume":"27","author":"Sanchez-Moya","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.05.012_bib0255","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ad.2015.01.010","article-title":"Risk of reactivation of hepatitis B virus infection in psoriasis patients treated with biologics: a retrospective analysis of 20 cases from the BIOBADADERM Database","volume":"106","author":"Sanz-Bueno","year":"2015","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2025.05.012_bib0260","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.jaad.2017.10.051","article-title":"Change over time in the rates of adverse events in patients receiving systemic therapy for psoriasis: a cohort study","volume":"78","author":"Descalzo","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.05.012_bib0265","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaad.2020.03.033","article-title":"Long-term safety of nine systemic medications for psoriasis: a cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry","volume":"83","author":"Dauden","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.05.012_bib0270","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1111\/jdv.14314","article-title":"Adverse events associated with discontinuation of the biologics\/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry Biobadaderm","volume":"31","author":"Belinchon","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.05.012_bib0275","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1080\/09546634.2021.1922572","article-title":"The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry","volume":"33","author":"Munera-Campos","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2025.05.012_bib0280","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jaad.2020.10.046","article-title":"Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: a Biobadaderm cohort analysis","volume":"84","author":"Baniandr\u00e9s-Rodr\u00edguez","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.05.012_bib0285","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jaad.2019.07.028","article-title":"The risk of urinary tract infections in patients with psoriasis on systemic medications in Biobadaderm Registry: a prospective cohort study","volume":"82","author":"Sahuquillo-Torralba","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.05.012_bib0290","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/bjd.14690","article-title":"Possible paradoxical occurrence of inflammatory arthritis in patients with psoriasis treated with biologics: findings in the Biobadaderm cohort","volume":"176","author":"Ruiz-Genao","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.012_bib0295","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ad.2015.04.013","article-title":"Escalera terap\u00e9utica en la psoriasis moderada y grave. \u00bfSolo hacia arriba? El porcentaje de pacientes con psoriasis grave tratados con biol\u00f3gicos se incrementa con el tiempo","volume":"106","author":"Carrascosa","year":"2015","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2025.05.012_bib0300","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.ad.2020.05.008","article-title":"Changing trends in drug prescription and causes of treatment discontinuation of first biologic over ten years in psoriasis in the Spanish Biobadaderm Registry","volume":"111","author":"Ruiz-Genao","year":"2020","journal-title":"Actas Dermosifiliog (Engl Ed)"},{"key":"10.1016\/j.ad.2025.05.012_bib0305","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ad.2016.08.003","article-title":"Manejo de los tratamientos biol\u00f3gicos en pacientes con psoriasis moderada-severa tratados mediante intervenciones quir\u00fargicas en el registro espa\u00f1ol BIOBADADERM","volume":"108","author":"Galiano Mejias","year":"2017","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2025.05.012_bib0310","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ad.2018.04.004","article-title":"Description of patients treated with biologic drugs as first-line systemic therapy in the BIOBADADERM registry between 2008 and 2016","volume":"109","author":"Carretero Hern\u00e1ndez","year":"2018","journal-title":"Actas Dermosifiliog (Engl Ed)"},{"key":"10.1016\/j.ad.2025.05.012_bib0315","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3109\/09546634.2015.1088130","article-title":"Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the Biobadaderm cohort","volume":"27","author":"Garc\u00eda-Doval","year":"2016","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.ad.2025.05.012_bib0320","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/jdv.12208","article-title":"Body Mass Index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal. Results of the Biobadaderm Registry","volume":"28","author":"Carrascosa","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.05.012_bib0325","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/jdv.14188","article-title":"Comparison of phenotype, comorbidities, therapy and adverse events between psoriatic patients with and without psoriatic arthritis. Biobadaderm registry","volume":"31","author":"Perez-Plaza","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.05.012_bib0330","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1111\/jdv.13682","article-title":"Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis","volume":"30","author":"Davila-Seijo","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.05.012_bib0335","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ad.2022.12.001","article-title":"Erythrodermic psoriasis has become less frequent: results from the Biobadaderm Registry","volume":"114","author":"Rivera-Diaz","year":"2023","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2025.05.012_bib0340","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/bjd.21763","article-title":"Differences in epidemiology, comorbidities and treatment choice between plaque psoriasis and pustular psoriasis: results from the BIOBADADERM registry","volume":"187","author":"Ruiz Genao","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.012_bib0345","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3711","article-title":"Effect of sex in systemic psoriasis therapy: differences in prescription effectiveness and safety in the BIOBADADERM Prospective Cohort","volume":"101","author":"Hern\u00e1ndez-Fern\u00e1ndez","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ad.2025.05.012_bib0350","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/bjd.18164","article-title":"Women with moderate-to-severe psoriasis in Spain (BIOBADADERM registry) show more than a 50% reduction in age-adjusted fertility rate when compared with the general population","volume":"181","author":"Gonzalez-Cantero","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.012_bib0355","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ad.2016.09.004","article-title":"Serie de casos de pacientes psori\u00e1sicas expuestas a terapia biol\u00f3gica durante el embarazo Registro BIOBADADERM y revisi\u00f3n de la literatura","volume":"108","author":"Echeverria-Garcia","year":"2017","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2025.05.012_bib0360","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1111\/jdv.17737","article-title":"Women with moderate-to-severe psoriasis in Spain (BIOBADADERM registry) breastfeed less when compared with general population","volume":"36","author":"Rivera-Diaz","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.05.012_bib0365","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ad.2021.05.017","article-title":"Moderate to severe psoriasis in pediatric and young patients: the BIOBADADERM Registry Experience","volume":"113","author":"Nieto Benito","year":"2022","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2025.05.012_bib0370","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/jdv.12688","article-title":"Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry","volume":"29","author":"Medina","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.05.012_bib0375","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/09546634.2018.1535690","article-title":"Safety and effectiveness of conventional systemic therapy and biological drugs in patients with moderate to severe psoriasis and HIV infection: a retrospective multicenter study","volume":"30","author":"Montes-Torres","year":"2019","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2025.05.012_bib0380","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/bjd.16715","article-title":"Cumulative exposure to biological therapy and risk of cancer in patients with psoriasis: a meta-analysis of Psonet studies from Israel, Italy Spain, the U.K. and Republic of Ireland","volume":"179","author":"Garcia-Doval","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.012_bib0385","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jaad.2016.07.039","article-title":"Risk of serious infections, cutaneous bacterial infections, and granulomatous infections in patients with psoriasis treated with anti-tumor necrosis factor agents versus classic therapies: prospective meta-analysis of Psonet registries","volume":"76","author":"Garcia-Doval","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.05.012_bib0390","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/bjd.12344","article-title":"Systemic psoriasis therapy shows high between-countries variation. A sign of unwarranted variation? Cross-sectional analysis of baseline data from the Psonet registries","volume":"169","author":"Garcia-Doval","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.012_bib0395","doi-asserted-by":"crossref","first-page":"516","DOI":"10.2340\/00015555-2586","article-title":"Factors associated with receiving biologics or classic systemic therapy for moderate-to-severe psoriasis: evidence from the PSONET Registries","volume":"97","author":"Davila-Seijo","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ad.2025.05.012_bib0400","doi-asserted-by":"crossref","first-page":"e075197","DOI":"10.1136\/bmjopen-2023-075197","article-title":"Drug survival and safety of biosimilars and originator adalimumab in the treatment of psoriasis: a multinational cohort study","volume":"13","author":"Phan","year":"2023","journal-title":"BMJ Open"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731025003722?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731025003722?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:32:05Z","timestamp":1762075925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731025003722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0001731025003722"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2025.05.012","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[Translated article] AEDV BIOBADADERM Registry: 15 Year-Contribution to Psoriasis Therapy Safety","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2025.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2024.11.027","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}